The main physical advantage of proton radiation therapy is the finite range of protons in the patient. However, proton treatment planning and delivery, as practiced today, is affected by considerable uncertainties in the range and therefore in the position of the distal dose fall-off region. Our overall goal is to utilize the physical proton advantage, i.e., the range, to its full extent in the clinic. We hypothesize that, mainly through the use of advanced imaging technology, we can reduce range uncertainties substantially, and control the depth position of the dose delivered to the patient to within 1 mm in the quasi-static case and within 3 mm in the presence of intra-fractional motion. We further hypothesize that this will lead to substantially improved target coverage and/or reduced dose to nearby critical structures. To meet the overall goal and test the hypotheses we will strive to achieve 3 Specific Aims.
Aim 1 is the reduction of range uncertainties in the static scenario. It involves the reduction of CT metal artifacts through a filtering approach and the use of higher energies. It also addresses the conversion of CT numbers to stopping powers, which are needed for accurate dose calculation. Monte Carlo dose calculation methods will be developed. We will not only aim to calculate the proton range with great precision, but also to investigate range degradation due to tissue heterogeneities, which leads to a reduced steepness of the distal dose fall-off.
Aim 2 is range control in the presence of organ motion. Here we will introduce spatio-temporal (4D) imaging techniques to analyze motion characteristics, and simulate organ motion in a numerical phantom. We will focus on gating strategies to mitigate the effects of the motion. We will also aim to improve positioning and immobilization accuracies, for example with optical imaging techniques.
The third aim i s to validate the achievable level of accuracy. This will be done in three ways. First we will investigate the feasibility and utility of in-vivo measurements using PET/CT scans taken directly after a proton treatment fraction. We will also do phantom measurements, both in a static phantom and in a biological motion phantom (swine lung). Finally, we will measure the residual range of an energetic proton beam after traversing the patient, and compare it with the expected value.
All Aims are generally applicable to both passively scattered proton therapy and IMPT. Overall this project will show to what degree the primary physical advantage of protons (i.e., the finite range) can be translated into a dosimetric advantage in patients. The clinical relevance of this will be studied in Project 1 and Project 2.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA021239-34
Application #
8736217
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (M1))
Project Start
1997-04-01
Project End
2014-07-31
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
34
Fiscal Year
2013
Total Cost
$204,108
Indirect Cost
$38,420
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Yock, Torunn I; Yeap, Beow Y; Ebb, David H et al. (2016) Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study. Lancet Oncol 17:287-98
Hong, Theodore S; Wo, Jennifer Y; Yeap, Beow Y et al. (2016) Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol 34:460-8
Eaton, Bree R; Esiashvili, Natia; Kim, Sungjin et al. (2016) Clinical Outcomes Among Children With Standard-Risk Medulloblastoma Treated With Proton and Photon Radiation Therapy: A Comparison of Disease Control and Overall Survival. Int J Radiat Oncol Biol Phys 94:133-8
Giantsoudi, Drosoula; Sethi, Roshan V; Yeap, Beow Y et al. (2016) Incidence of CNS Injury for a Cohort of 111 Patients Treated With Proton Therapy for Medulloblastoma: LET and RBE Associations for Areas of Injury. Int J Radiat Oncol Biol Phys 95:287-96
Park, Yang-Kyun; Sharp, Gregory C (2016) Gain Correction for an X-ray Imaging System With a Movable Flat Panel Detector and Intrinsic Localization Crosshair. Technol Cancer Res Treat 15:387-95
Bentefour, El H; Tang, Shikui; Cascio, Ethan W et al. (2015) Validation of an in-vivo proton beam range check method in an anthropomorphic pelvic phantom using dose measurements. Med Phys 42:1936-47
Doolan, P J; Testa, M; Sharp, G et al. (2015) Patient-specific stopping power calibration for proton therapy planning based on single-detector proton radiography. Phys Med Biol 60:1901-17
Min, Chul Hee; Zhu, Xuping; Grogg, Kira et al. (2015) A Recommendation on How to Analyze In-Room PET for In Vivo Proton Range Verification Using a Distal PET Surface Method. Technol Cancer Res Treat 14:320-5
Grogg, Kira; Alpert, Nathaniel M; Zhu, Xuping et al. (2015) Mapping (15)O production rate for proton therapy verification. Int J Radiat Oncol Biol Phys 92:453-9
Chen, Huixiao; Winey, Brian A; Daartz, Juliane et al. (2015) Efficiency gains for spinal radiosurgery using multicriteria optimization intensity modulated radiation therapy guided volumetric modulated arc therapy planning. Pract Radiat Oncol 5:49-55

Showing the most recent 10 out of 248 publications